EMA gives nod to AZ/BMS diabetes pill

Drugmakers got some good news from the European Medicines Agency today. AstraZeneca ($AZ) and Bristol-Myers Squibb ($BMY) garnered a positive opinion from the EMA on the companies' bid to gain approval for Komboglyze, a therapy for type 2 diabetes that combines the blood sugar-lowering drugs, Onglyza and metformin. The drug was approved in the U.S. last year. The European Commission is likely decide the market fate of the combo therapy, which is taken once a day in a single pill, in the coming months. Reuters article

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.